# Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Study · id `cardio:ct-nct02957682` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02957682](<https://clinicaltrials.gov/study/NCT02957682>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02957682

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2176 participants.

## Technical summary

Registry record NCT02957682. Randomized; quadruple masking; primary purpose treatment. Start 2016-11-02 (actual); primary completion 2020-03-05 (actual). Results posted on 2021-05-07.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2176 participants (enrolled count; ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Started: 2016-11-02 (actual) (ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Primary completion: 2020-03-05 (actual) (ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Completion: 2020-03-05 (actual) (ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Results first posted: 2021-05-07 (ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Chile; Estonia; Japan; Mexico; Russia; South Africa; Ukraine (ClinicalTrials.gov record NCT02957682, source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02957682-2021-05-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
- Condition: Hypercholesterolemia
- Intervention (Drug): Praluent (Alirocumab)
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: ef7990a3330ca949e0f5f6123302beb6e0254f54e68096efb2c1d176c7f120cd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
